Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials (3:02).
20-06-2022 | EULAR 2022 | Conference coverage | Video